Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension. The company is also developing OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; and OTX-TKI, a tyrosine kinase inhibitor intravitreal injection that delivers a hydrogel-based anti-angiogenic formulation for the treatment of wet age-related macular degeneration. In addition, it markets ReSure Sealant, a hydrogel-based ophthalmic wound sealant to seal corneal incisions following cataract surgery. Further, the company engages in the preclinical development of formulations of its hydrogel administered via intravitreal injection to address the diseases and conditions of the back of the eye. Ocular Therapeutix, Inc. has collaboration agreement with Regeneron Pharmaceuticals, Inc. for the development and commercialization of products using its hydrogel in combination with large molecule VEGF-targeting compounds for the treatment of retinal diseases. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-357-4000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.92 million
Profitability
Miscellaneous
Employees119
OptionableOptionable
Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions
What is Ocular Therapeutix's stock symbol?
Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."
How were Ocular Therapeutix's earnings last quarter?
Ocular Therapeutix Inc (NASDAQ:OCUL) posted its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.37). The biopharmaceutical company had revenue of $0.65 million for the quarter, compared to the consensus estimate of $0.35 million. Ocular Therapeutix had a negative return on equity of 133.73% and a negative net margin of 2,822.15%. View Ocular Therapeutix's Earnings History.
When is Ocular Therapeutix's next earnings date?
What price target have analysts set for OCUL?
7 brokerages have issued 12 month price targets for Ocular Therapeutix's shares. Their forecasts range from $9.00 to $24.00. On average, they anticipate Ocular Therapeutix's share price to reach $13.60 in the next year. This suggests a possible upside of 271.6% from the stock's current price. View Analyst Price Targets for Ocular Therapeutix.
What is the consensus analysts' recommendation for Ocular Therapeutix?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ocular Therapeutix.
What are Wall Street analysts saying about Ocular Therapeutix stock?
Here are some recent quotes from research analysts about Ocular Therapeutix stock:
- 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (2/14/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $573M, which includes a discounted cash flow-based asset value of $580M for DEXTENZA, OTX-TP and ReSure, and excludes projected debt position of $7M at the end of 2019, using a 15% discount rate and 2% terminal growth rate, and assuming 47.7M shares outstanding at the end of 2019. Probabilities of success ascribed to post-surgical ocular pain and inflammation, allergic conjunctivitis and glaucoma are 100%, 40% and 40%, respectively." (12/4/2018)
- 3. Cantor Fitzgerald analysts commented, "We rate Ocular Therapeutix (OCUL) 12-month price target of $22 per share. Ocular focuses on a platform of sustained drug-delivered therapies for the treatment of ocular diseases and conditions. Ocular’s lead development product, DEXTENZA, is an intracanalicular dexamethasone insert therapy for the treatment of post-surgical ocular pain. We believe Ocular could receive FDA approval in 2018. Valuation Summary We arrive at our 12-month price target of $22/share by assessing the after-tax, risk- adjusted NPV of future cash flows from DEXTENZA." (7/19/2018)
Has Ocular Therapeutix been receiving favorable news coverage?
Media coverage about OCUL stock has trended positive on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ocular Therapeutix earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days.
Who are some of Ocular Therapeutix's key competitors?
Some companies that are related to Ocular Therapeutix include Basilea Pharmaceutica (BPMUF), CymaBay Therapeutics (CBAY), Crinetics Pharmaceuticals (CRNX), Assembly Biosciences (ASMB), AMAG Pharmaceuticals (AMAG), Lexicon Pharmaceuticals (LXRX), Aurinia Pharmaceuticals (AUPH), Urogen Pharma (URGN), Kura Oncology (KURA), Eidos Therapeutics (EIDX), Karyopharm Therapeutics (KPTI), Akorn (AKRX), Flexion Therapeutics (FLXN), ChemoCentryx (CCXI) and Synthorx (THOR).
Who are Ocular Therapeutix's key executives?
Ocular Therapeutix's management team includes the folowing people:
- Dr. Amarpreet Sawhney, Founder & Exec. Chairman (Age 52)
- Mr. Antony Mattessich, Pres, CEO & Director (Age 52)
- Mr. Donald Notman Jr., Chief Financial Officer
- Dr. Michael H. Goldstein, Chief Medical Officer (Age 52)
- Mr. Kevin F. Hanley, Sr. VP of Technical Operations (Age 57)
Who are Ocular Therapeutix's major shareholders?
Ocular Therapeutix's stock is owned by a number of of retail and institutional investors. Top institutional investors include Summer Road LLC (9.17%), BlackRock Inc. (6.77%), Jennison Associates LLC (3.95%), Deltec Asset Management LLC (1.76%), Northern Trust Corp (0.98%) and Geode Capital Management LLC (0.85%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman and Kevin F Hanley. View Institutional Ownership Trends for Ocular Therapeutix.
Which major investors are selling Ocular Therapeutix stock?
Which major investors are buying Ocular Therapeutix stock?
OCUL stock was purchased by a variety of institutional investors in the last quarter, including Summer Road LLC, BlackRock Inc., Deltec Asset Management LLC, Two Sigma Investments LP, Millennium Management LLC, Geode Capital Management LLC, Bank of America Corp DE and Rhumbline Advisers. Company insiders that have bought Ocular Therapeutix stock in the last two years include Amarpreet Sawhney, Antony C Mattessich, Daniel M Bollag, Donald Notman and Kevin F Hanley. View Insider Buying and Selling for Ocular Therapeutix.
How do I buy shares of Ocular Therapeutix?
Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ocular Therapeutix's stock price today?
One share of OCUL stock can currently be purchased for approximately $3.66.
How big of a company is Ocular Therapeutix?
Ocular Therapeutix has a market capitalization of $151.09 million and generates $1.92 million in revenue each year. The biopharmaceutical company earns $-63,380,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Ocular Therapeutix employs 119 workers across the globe.
What is Ocular Therapeutix's official website?
How can I contact Ocular Therapeutix?
Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at 781-357-4000 or via email at [email protected]
MarketBeat Community Rating for Ocular Therapeutix (NASDAQ OCUL)
MarketBeat's community ratings are surveys of what our community members think about Ocular Therapeutix and other stocks. Vote "Outperform" if you believe OCUL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCUL will underperform the S&P 500 over the long term. You may vote once every thirty days.
